BAXTER INTERNATIONAL INC. Funds and ETFs Baxter International Inc.
Equities
BAX
US0718131099
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.42 USD | +0.50% |
|
-2.44% | -8.85% |
| 05-13 | Baxter International's Clinolipid Injection Approved for Expanded Use in US | MT |
| 05-10 | TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 | MT |
ETFs positioned on Baxter International Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.07% | 254 M€ | +10.27% | - | |
| 1.87% | 9 M€ | 0.00% | ||
| 1.23% | 17 M€ | +7.01% | - | |
| 0.81% | 4 M€ | +20.15% | ||
| 0.75% | 8 M€ | +4.88% | ||
| 0.73% | 2 M€ | +9.27% | ||
| 0.40% | 9 M€ | -.--% | - | |
| 0.38% | 1 M€ | +2.21% | - | |
| 0.24% | 5 M€ | -72.95% | - | |
| 0.19% | 2,383 M€ | +13.05% | ||
| 0.19% | 7 M€ | +0.11% | - | |
| 0.16% | 9 M€ | +9.41% | ||
| 0.15% | 8 M€ | +5.15% | - | |
| 0.15% | 744 M€ | +8.72% | ||
| 0.14% | 4 M€ | -.--% | - | |
| 0.13% | 264 M€ | -.--% | - | |
| 0.13% | 187 M€ | +9.40% | - | |
| 0.13% | 477 M€ | +11.85% | ||
| 0.13% | 1,448 M€ | -.--% | - | |
| 0.13% | 219 M€ | +17.17% | - | |
| 0.12% | 330 M€ | -.--% | ||
| 0.11% | 253 M€ | +7.47% | ||
| 0.11% | 26 M€ | +20.69% | - | |
| 0.11% | 85 M€ | +11.59% | - | |
| 0.10% | 26 M€ | +16.85% | - |
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows:
- medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.);
- kidney dialysis drugs and equipment (30.1%);
- systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.;
- other (20.1%).
Export accounts for 52.7% of net sales.
Calendar
15/05/2024
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
35.24
USD
Average target price
46.47
USD
Spread / Average Target
+31.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.85% | 17.96B | |
| -5.51% | 181B | |
| +2.33% | 112B | |
| -3.62% | 67.92B | |
| +1.52% | 50.1B | |
| +8.06% | 44.27B | |
| +9.39% | 40.41B | |
| +23.35% | 31.95B | |
| +0.67% | 25.82B | |
| +17.27% | 25.29B |
- Stock Market
- Equities
- BAX Stock
- Funds and ETFs Baxter International Inc.
